Bicara Therapeutics reported increased net losses for Q4 and full year 2025, selected an optimal dose for its pivotal Phase 3 trial, and expects its cash to fund operations into the first half of 2029.
Key takeaways
Net loss was $37.4 million for Q4 2025, compared to $21.0 million for Q4 2024.
Net loss was $138.0 million for the full year 2025, compared to $68.0 million for the full year 2024.
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial.
Expects substantial enrollment in the FORTIFI-HN01 pivotal study by the end of 2026 to enable an interim analysis readout in mid-2027.
Cash, cash equivalents and marketable securities were $414.8 million as of December 31, 2025, with an expected cash runway into the first half of 2029.
Raised net proceeds of $161.8 million through an oversubscribed public offering in the first quarter of 2026.